A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1

2010/08/30 by Jamie Wilson, J R F Wilson, A C Bateman +13 · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Cancer-related Molecular Pathways #BRCA gene mutations in cancer #Cancer Risks and Factors

paper · doi:10.1136/jmg.2010.078113

Abstract

INTRODUCTION: The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages. Basal (triple negative) breast cancers are now well recognised to be a typical sub-type of breast cancer developing in a large proportion of BRCA1 gene carriers. We considered whether a similar narrow sub-type of breast cancer was found in TP53 gene mutation carriers. OBJECTIVE: A hypothesis generating study to investigate whether there are specific breast tumour characteristics associated with germline TP53 mutations. METHODS: Pathological characteristics in 12 breast cancers arising in nine patients carrying pathogenic TP53 mutations were compared to a reference panel of 231 young onset breast tumours included in the POSH study. RESULTS: Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%); ER and PR status were equivalent between groups. CONCLUSION: These findings suggest that breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.

Cited by

• Early onset HER2-positive breast cancer is associated with germline TP53 mutations. [europepmc]
• Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. [europepmc]
• Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. [europepmc]
• Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions. [europepmc]
• Prevalence of germline TP53 mutations in HER2+ breast cancer patients. [europepmc]
• Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. [europepmc]
• The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. [europepmc]
• A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis. [europepmc]
• TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer. [europepmc]
• Mutant p53 gain of function induces HER2 over-expression in cancer cells. [europepmc]
• Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). [europepmc]
• Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. [europepmc]
• An Insight Into the Molecular Mechanism of Berberine Towards Multiple Cancer Types Through Systems Pharmacology. [europepmc]
• Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. [europepmc]
• Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. [europepmc]
• Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. [europepmc]
• Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. [europepmc]
• Attenuation of p53 mutant as an approach for treatment Her2-positive cancer. [europepmc]
• Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. [europepmc]
• Germline TP53 Testing in Breast Cancers: Why, When and How? [europepmc]
• New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer. [europepmc]
• Risks and Function of Breast Cancer Susceptibility Alleles. [europepmc]
• Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study. [europepmc]
• Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers. [europepmc]
• Genomic disparities between cancers in adolescent and young adults and in older adults. [europepmc]

Related

• High frequency of de novo mutations in Li–Fraumeni syndrome
• Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer
• Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
• Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer
• Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification